Unicycive Therapeutics Receives FDA Complete Response Letter for Oxylanthanum Carbonate NDA
· david shapiro
Source Summary
FDA did not raise concerns regarding the clinical efficacy or safety data of OLC, and no additional data was requested
Advertisement